Terms: = Bone cancer AND CBL, RNF55, 867, ENSG00000110395, C-CBL, CBL2 AND Treatment
38 results:
1. Three-Dimensional Multimodality Image Reconstruction as Teaching Tool for Case-based learning among medical postgraduates: a focus on primary pelvic bone Tumour Education.
Hu X; Wang Y; Li J; Qing P; Yang X; Zeng J; Min L; Tu C
BMC Med Educ; 2023 Dec; 23(1):944. PubMed ID: 38087270
[TBL] [Abstract] [Full Text] [Related]
2. Long term outcome of surgical treatment of chondroblastoma: analysis of local control and growth plate/articular cartilage related complications.
Muratori F; Scanferla R; Roselli G; Frenos F; Campanacci DA
BMC Musculoskelet Disord; 2023 Feb; 24(1):139. PubMed ID: 36814214
[TBL] [Abstract] [Full Text] [Related]
3. Development and externally validate MRI-based nomogram to assess EGFR and T790M mutations in patients with metastatic lung adenocarcinoma.
Fan Y; Dong Y; Wang H; Wang H; Sun X; Wang X; Zhao P; Luo Y; Jiang X
Eur Radiol; 2022 Oct; 32(10):6739-6751. PubMed ID: 35729427
[TBL] [Abstract] [Full Text] [Related]
4. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
Tefferi A; Gangat N; Pardanani A; Crispino JD
Cancer Res; 2022 Mar; 82(5):749-763. PubMed ID: 34911786
[TBL] [Abstract] [Full Text] [Related]
5. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
Pullarkat ST; Wu W; Pullarkat V
Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
[TBL] [Abstract] [Full Text] [Related]
6. The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.
Park HS; Son BR; Shin KS; Byeon S; Kim HK; Yang Y; Jeong Y; Han HS; Lee KH; Kwon J
Acta Haematol; 2021; 144(6):649-659. PubMed ID: 34233332
[TBL] [Abstract] [Full Text] [Related]
7. Having a co-morbidity predicts worse outcome in early rheumatoid arthritis despite intensive treatment: a post hoc evaluation of the pragmatic randomized controlled CareRA trial.
Stouten V; Westhovens R; De Cock D; Van der Elst K; Pazmino S; Bertrand D; Joly J; Verschueren P
Rheumatology (Oxford); 2021 Aug; 60(8):3699-3708. PubMed ID: 33434277
[TBL] [Abstract] [Full Text] [Related]
8. Risk factors and predictors for tumor site origin in metastatic adenocarcinoma of unknown primary site.
Li X; Shao Y; Sheng L; Zhu J; Wang Z; Guo K; Sun L
Cancer Med; 2021 Feb; 10(3):974-988. PubMed ID: 33405390
[TBL] [Abstract] [Full Text] [Related]
9. Risk factors for osteonecrosis of the femoral head in brain tumor patients receiving corticosteroid after surgery.
Lim SJ; Yeo I; Park CW; Lee H; Park YS; Lee JI
PLoS One; 2020; 15(9):e0238368. PubMed ID: 32881966
[TBL] [Abstract] [Full Text] [Related]
10. Spontaneous Rib Fractures After Breast cancer treatment Based on bone Scans: Comparison Of Conventional Versus Hypofractionated Radiotherapy.
Kim DW; Kim JS; Kim K; Shin KH
Clin Breast Cancer; 2021 Feb; 21(1):e80-e87. PubMed ID: 32800490
[TBL] [Abstract] [Full Text] [Related]
11. Cost-effectiveness analysis of proton beam therapy for treatment decision making in paranasal sinus and nasal cavity cancers in China.
Li G; Qiu B; Huang YX; Doyen J; Bondiau PY; Benezery K; Xia YF; Qian CN
BMC Cancer; 2020 Jun; 20(1):599. PubMed ID: 32590957
[TBL] [Abstract] [Full Text] [Related]
12. Long-acting octreotide treatment has no impact on tumor uptake of 99mTc-HYNIC-TOC in patients with neuroendocrine tumors.
Li Y; Xu J; Xu X; Zhang J; Zhang Y
Nucl Med Commun; 2019 Oct; 40(10):1005-1010. PubMed ID: 31365494
[TBL] [Abstract] [Full Text] [Related]
13. MRI-based tumour control probability in skull-base chordomas treated with carbon-ion therapy.
Buizza G; Molinelli S; D'Ippolito E; Fontana G; Pella A; Valvo F; Preda L; Orecchia R; Baroni G; Paganelli C
Radiother Oncol; 2019 Aug; 137():32-37. PubMed ID: 31051372
[TBL] [Abstract] [Full Text] [Related]
14. Efficacy and Tolerability of CyberKnife Stereotactic Robotic Radiotherapy for Primary or Secondary Orbital Lesions: A Single-Center Retrospective Experience.
Desideri I; Francolini G; Carta GA; Di Cataldo V; Masi L; Meattini I; Bonomo P; Loi M; Greto D; Visani L; Lo Russo M; Grassi R; Teriaca MA; Garlatti P; Nardi C; Livi L
Technol Cancer Res Treat; 2019 Jan; 18():1533033818818561. PubMed ID: 30803353
[TBL] [Abstract] [Full Text] [Related]
15. C-cbl and cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Luo P; Wang X; Zhou J; Li L; Jing Z
Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
[TBL] [Abstract] [Full Text] [Related]
16. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.
Bolouri H; Farrar JE; Triche T; Ries RE; Lim EL; Alonzo TA; Ma Y; Moore R; Mungall AJ; Marra MA; Zhang J; Ma X; Liu Y; Liu Y; Auvil JMG; Davidsen TM; Gesuwan P; Hermida LC; Salhia B; Capone S; Ramsingh G; Zwaan CM; Noort S; Piccolo SR; Kolb EA; Gamis AS; Smith MA; Gerhard DS; Meshinchi S
Nat Med; 2018 Jan; 24(1):103-112. PubMed ID: 29227476
[TBL] [Abstract] [Full Text] [Related]
17. Pattern of relapse in paediatric acute lymphoblastic leukaemia in a tertiary care unit.
Siddiqui EU; Kazi SG; Habib MI; Ahmed Khan KM; Zia N
J Pak Med Assoc; 2016 Aug; 66(8):961-7. PubMed ID: 27524528
[TBL] [Abstract] [Full Text] [Related]
18. Long non-coding RNA tumor suppressor candidate 7 functions as a tumor suppressor and inhibits proliferation in osteosarcoma.
Cong M; Li J; Jing R; Li Z
Tumour Biol; 2016 Jul; 37(7):9441-50. PubMed ID: 26781978
[TBL] [Abstract] [Full Text] [Related]
19. The genomic landscape of juvenile myelomonocytic leukemia.
Stieglitz E; Taylor-Weiner AN; Chang TY; Gelston LC; Wang YD; Mazor T; Esquivel E; Yu A; Seepo S; Olsen S; Rosenberg M; Archambeault SL; Abusin G; Beckman K; Brown PA; Briones M; Carcamo B; Cooper T; Dahl GV; Emanuel PD; Fluchel MN; Goyal RK; Hayashi RJ; Hitzler J; Hugge C; Liu YL; Messinger YH; Mahoney DH; Monteleone P; Nemecek ER; Roehrs PA; Schore RJ; Stine KC; Takemoto CM; Toretsky JA; Costello JF; Olshen AB; Stewart C; Li Y; Ma J; Gerbing RB; Alonzo TA; Getz G; Gruber T; Golub T; Stegmaier K; Loh ML
Nat Genet; 2015 Nov; 47(11):1326-1333. PubMed ID: 26457647
[TBL] [Abstract] [Full Text] [Related]
20. Fasudil, a clinically safe ROCK inhibitor, decreases disease burden in a cbl/cbl-b deficiency-driven murine model of myeloproliferative disorders.
William BM; An W; Feng D; Nadeau S; Mohapatra BC; Storck MA; Band V; Band H
Hematology; 2016 May; 21(4):218-24. PubMed ID: 26177294
[TBL] [Abstract] [Full Text] [Related]
[Next]
